Payment overview · 2025
General Payments
$1,062.22
26 reported records · 4 companies
Healthcare provider profile · identity verified
Eddie A Lim, M.D.
Allopathic & Osteopathic Physicians|General Practice · HONOLULU, HI · NPI 1164439683
Verified facts
What the public records show
CMS Open Payments records show Eddie A Lim, M.D. received $1,062.22 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $471.72 | 44.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $278.86 | 26.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $213.87 | 20.1% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $97.77 | 9.2% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,062.22 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $278.86 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $257.33 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $214.39 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $179.58 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $95.17 | 6 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
119 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 126 |
| Losartan Potassium | Losartan Potassium | 471 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 81 |
| Omeprazole | Omeprazole | 249 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 43 |
| Livalo | Pitavastatin Calcium | 204 | 35 |
| Raloxifene Hcl | Raloxifene Hcl | 160 | 28 |
| Allopurinol | Allopurinol | 136 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 27 |
| Metformin Hcl Er | Metformin Hcl | 122 | 34 |
| Vemlidy | Tenofovir Alafenamide | 119 | 12 |
| Rybelsus | Semaglutide | 101 | 23 |
| Meclizine Hcl | Meclizine Hcl | 98 | 45 |
| Fenofibrate | Fenofibrate | 95 | 24 |
| Edarbi | Azilsartan Medoxomil | 93 | 17 |
| Irbesartan | Irbesartan | 93 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 20 |
| Linzess | Linaclotide | 86 | 25 |
| Alcohol Pads | Alcohol Antiseptic Pads | 83 | 34 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 83 | 16 |
| Alendronate Sodium | Alendronate Sodium | 77 | 24 |
| Jardiance | Empagliflozin | 77 | 17 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 68 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 67 | 13 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 66 | 14 |
| Farxiga | Dapagliflozin Propanediol | 66 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 66 | 11 |
| Vascepa | Icosapent Ethyl | 65 | 14 |
| Hydrocortisone | Hydrocortisone | 64 | 45 |
| Trazodone Hcl | Trazodone Hcl | 62 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 13 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 56 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 17 |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Naproxen | Naproxen | 50 | 28 |
| Synjardy | Empagliflozin/Metformin Hcl | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Gabapentin | Gabapentin | 42 | 15 |
| Simvastatin | Simvastatin | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Loperamide | Loperamide Hcl | 40 | 27 |
| Meloxicam | Meloxicam | 37 | 13 |
| Metformin Hcl | Metformin Hcl | 35 | suppressed |
| Prolia | Denosumab | 32 | 22 |
| Finasteride | Finasteride | 31 | suppressed |
| Lisinopril | Lisinopril | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Furosemide | Furosemide | 22 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 21 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,062.22 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, Kerendia, LINZESS | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error